ALCON INC (ALC) Stock Price, Forecast & Analysis
USA • New York Stock Exchange • NYSE:ALC • CH0432492467
ALC Key Statistics, Chart & Performance
The current stock price of ALC is 78.37 USD. In the past month the price decreased by -3.27%. In the past year, price decreased by -12.49%.
ALC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALC. When comparing the yearly performance of all stocks, ALC is a bad performer in the overall market: 69.63% of all stocks are doing better.
ALC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALC. ALC has an excellent profitability rating, but there are some minor concerns on its financial health.
ALC Financial Highlights
Over the last trailing twelve months ALC reported a non-GAAP Earnings per Share(EPS) of 3. The EPS decreased by -0.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.28% | ||
| ROA | 3.32% | ||
| ROE | 4.74% | ||
| Debt/Equity | 0.21 |
ALC Forecast & Estimates
19 analysts have analysed ALC and the average price target is 107.72 USD. This implies a price increase of 37.45% is expected in the next year compared to the current price of 78.37.
For the next year, analysts expect an EPS growth of 0.91% and a revenue growth 5.17% for ALC
ALC Ownership
ALC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.56 | 16.088B | ||
| SOLV | SOLVENTUM CORP | 11.87 | 13.267B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.68 | 11.573B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.29 | 4.706B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.44 | 4.372B | ||
| ICUI | ICU MEDICAL INC | 18.24 | 3.703B | ||
| HAE | HAEMONETICS CORP/MASS | 11.77 | 3.087B | ||
| XRAY | DENTSPLY SIRONA INC | 7.92 | 2.502B | ||
| NEOG | NEOGEN CORP | 31.7 | 2.29B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.56 | 1.968B |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALC
Company Profile
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,599 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
Company Info
ALCON INC
Rue Louis d'Affry 6
Fribourg FRIBOURG 1701 CH
CEO: David J. Endicott
Employees: 25000
Phone: 41589113800
ALCON INC / ALC FAQ
Can you describe the business of ALCON INC?
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,599 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
What is the stock price of ALCON INC today?
The current stock price of ALC is 78.37 USD. The price decreased by -0.87% in the last trading session.
Does ALCON INC pay dividends?
ALCON INC (ALC) has a dividend yield of 0.45%. The yearly dividend amount is currently 0.26.
What is the ChartMill rating of ALCON INC stock?
ALC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for ALCON INC?
ALCON INC (ALC) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Is ALCON INC (ALC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALC.
Is ALCON INC (ALC) expected to grow?
The Revenue of ALCON INC (ALC) is expected to grow by 5.17% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.